What is the connection between hormone substitution therapy and breast cancer?

For several decades, hormone substitution therapy (HRT) has been considered a gold standard treatment for menopausal women to reduce symptoms such as heat pitfalls, mood distortion, vaginal dryness and more. The combination of estrogen and progestin was often used and considered safe for women. Since 2002, the safety of this treatment has been repeatedly questioned because statistically significant studies have shown that HRT has many risk factors. Among them, hormone substitution therapy and the risk of breast cancer often go hand in hand, and many doctors now consider HRT to be the treatment of the last resort instead of the first preference.

The following studies have verified that hormone substitution therapy and breast cancer are connected. In particular, there is evidence that HRT can increase tumors, but the results of the mammogram are less visible. This means that women will be more likely to diagnose breast cancer in later stages of the disease where the probability of complete remission or treatment nOuthane high. Estrogens in HRT are assumed to contribute to cancer growth in approximately 66% of tumors because these cancer contain estrogen receptors. Providing estrogen tumor feed and can increase its size and strength.

Further research in 2010 suggests that the connection between hormone substitution therapy and breast cancer is strengthened with the length of use. Long -term HRT users who are defined as HRT use for five or more years are more likely to gain breast cancer and develop more aggressive types that increase mortality. This would suggest that if HRT was to be used at all, the planned use time should be very short. In the past, many women have remained on these treatments for ten years or more, which significantly increases the risk of timely mortality due to breast cancer or other cancer.

Evidence assembled in a series of studyClear correlations between hormone substitution therapy and breast cancer, but HRT is still available in most areas. For example, in the US, hormonal therapy may be used after complete hysterectomy or could be recommended if osteoporosis is severe. Its permanent availability leaves open outside the brand, more traditional use for menopausal symptoms, and doctors can still prescribe or recommend patients. It may be guaranteed, but its potential for life -threatening adverse effects must be fully considered to be fully considered before use.

There are also several questions about the safety of hormonal contraceptives that use the same hormones. Until now, there is a remarkable slight increase in breast cancer risk, which lasts approximately 10 years after the last use, but then tends to normalize in women who have not used hormonal contraceptives. It is still unknown whether hormonal contraceptives and then HRT could have a cumulative effect that the heirizico of the ghhten breast cancer.Perhaps the expansion of normal hormones in the years when women produce them are less dangerous than their addition after the production of these hormones.